Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| CSBR | CHAMPIONS ONCOLOGY, INC. | 2025-12-31 16:00:38 | 6.91 | 0 | 0 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CSBR | 0000771856 | CHAMPIONS ONCOLOGY, INC. | US15870P3073 | 549300O8WKLP8QEG5U47 | 521401755 | Nasdaq | 2836 | Biological Products, (No Diagnostic Substances) | 0430 | DE | 855 N. WOLFE STREET | BALTIMORE | MD | 21205 | UNITED STATES | US | 410-369-0365 | 855 N. WOLFE STREET, BALTIMORE, MD, 21205 | 855 N. WOLFE STREET, BALTIMORE, MD, 21205 | CHAMPIONS BIOTECHNOLOGY, INC. | — | 2007 | — | — | — | 15,400,000 | 13,908,754 | 13,788,421 | Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist. | 2025-12-25 20:59:30 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 15,400,000 | -6,600,000 | -30 | 13,777,170 | 183,404 | 1.3492 |
| 2024 | 22,000,000 | -6,000,000 | -21.4286 | 13,593,766 | 134,227 | 0.9973 |
| 2023 | 28,000,000 | -16,000,000 | -36.3636 | 13,459,539 | -62,902 | -0.4652 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Brady Davis | President | 2025 | 177,083 | 0 | 0 | — | 0 | 177,083 |
| David Miller | Chief Financial Officer | 2025 | 278,333 | 30,000 | 0 | — | 0 | 315,777 |
| Ronnie Morris | Chief Executive Officer | 2025 | 400,000 | 200,000 | 0 | — | 0 | 600,000 |
| David Miller | Chief Financial Officer | 2024 | 260,000 | 0 | 0 | — | 0 | 260,000 |
| Brady Davis | President | 2024 | 425,000 | 75,000 | 0 | — | 0 | 1,346,210 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 213 |
| 2024 | 210 |
| 2023 | 230 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 56,944,000 | 50,155,000 | 53,870,000 |
| Cost Of Revenue | 28,389,000 | 29,401,000 | 29,532,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 6,825,000 | 9,544,000 | 11,545,000 |
| General And Administrative Expenses | 9,339,000 | 11,067,000 | 10,240,000 |
| Operating Expenses | — | — | — |
| Operating Income | 4,553,000 | -7,356,000 | -5,256,000 |
| Net Income | 4,701,000 | -7,276,000 | -5,335,000 |
| Earnings Per Share Basic | 0.34 | -0.54 | -0.39 |
| Earnings Per Share Diluted | 0.33 | -0.54 | -0.39 |
| Weighted Average Shares Outstanding Basic | 13,659,786 | 13,547,604 | 13,541,559 |
| Weighted Average Shares Outstanding Diluted | 14,266,781 | 13,547,604 | 13,541,559 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 9,785,000 | 2,618,000 | 10,118,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 11,234,000 | 9,526,000 | 3,843,000 |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 22,369,000 | 13,639,000 | 19,457,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | — | — | — |
| Other Assets Non Current | 185,000 | 185,000 | 15,000 |
| Total Assets Non Current | 9,975,000 | 12,493,000 | 14,854,000 |
| Total Assets | 32,344,000 | 26,132,000 | 34,311,000 |
| Accounts Payable | 4,248,000 | 5,800,000 | 5,334,000 |
| Deferred Revenue | 15,443,000 | 12,094,000 | 12,776,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 135,000 | 150,000 | 2,270,000 |
| Total Liabilities Current | 23,853,000 | 21,541,000 | 21,733,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 85,000 | 401,000 | 551,000 |
| Total Liabilities Non Current | 4,719,000 | 6,494,000 | 7,942,000 |
| Total Liabilities | 28,572,000 | 28,035,000 | 29,675,000 |
| Common Stock | 14,000 | 14,000 | 14,000 |
| Retained Earnings | -79,892,000 | -84,593,000 | -77,317,000 |
| Accumulated Other Comprehensive Income | — | — | — |
| Total Shareholders Equity | 3,772,000 | -1,903,000 | 4,636,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 1,640,000 | 1,867,000 | 2,246,000 |
| Share Based Compensation Expense | 654,000 | 1,118,000 | 864,000 |
| Other Non Cash Income Expense | -293,000 | -435,000 | 0 |
| Change In Accounts Receivable | 1,436,000 | 1,991,000 | -1,308,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -1,749,000 | 465,000 | 2,465,000 |
| Change In Other Liabilities | 395,000 | -109,000 | -145,000 |
| Cash From Operating Activities | 7,386,000 | -6,137,000 | 3,972,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 389,000 | 836,000 | 2,872,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -389,000 | -836,000 | -2,872,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | 0 | 634,000 | 74,000 |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 170,000 | -527,000 | 11,000 |
| Change In Cash | 7,167,000 | -7,500,000 | 1,111,000 |
| Cash At End Of Period | 9,785,000 | 2,618,000 | 10,118,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | — | — | — |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 0.34 | -0.54 | -0.39 |
| Price To Earnings Ratio | 21.0294 | -8.9815 | -12.4615 |
| Earnings Growth Rate | -162.963 | 38.4615 | -1,075 |
| Price Earnings To Growth Ratio | -0.129 | -0.2335 | 0.0116 |
| Book Value Per Share | 0.2761 | -0.1405 | 0.3424 |
| Price To Book Ratio | 25.8928 | -34.5275 | 14.1959 |
| Ebitda | 6,341,000 | -5,409,000 | -3,089,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | — | — | — |
| Free Cash Flow | — | — | — |
| Return On Equity | 1.2463 | 3.8234 | -1.1508 |
| One Year Beta | 0.8282 | -0.2535 | 0.2607 |
| Three Year Beta | 0.4064 | 0.2183 | 0.485 |
| Five Year Beta | 0.5026 | 0.7912 | 0.9311 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| ACKERMAN JOEL | Director | 2025-11-05 | 21,216 | A | 21,216 |
| TOBIN SCOTT R | Director, 10% owner | 2025-11-05 | 25,460 | A | 25,460 |
| Mendelson Daniel Newman | Director | 2025-11-05 | 13,790 | A | 13,790 |
| SIDRANSKY DAVID | Director | 2025-11-05 | 21,216 | A | 21,216 |
| Breitfeld Philip P. | Director | 2025-11-05 | 13,790 | A | 13,790 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| JPMORGAN CHASE & CO | 2025-09-30 | 71 | 11 | 6.4545 |
| BATTERY MANAGEMENT CORP. | 2025-09-30 | 15,680,333 | 2,421,673 | 6.475 |
| NEA Management Company, LLC | 2025-09-30 | 11,096,337 | 1,713,720 | 6.475 |
| CITADEL ADVISORS LLC | 2025-09-30 | 105,711 | 16,326 | 6.475 |
| MILLENNIUM MANAGEMENT LLC | 2025-09-30 | 81,812 | 12,635 | 6.475 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Dimensional ETF Trust | 2025-10-31 | Dimensional US Core Equity 1 ETF | DCOR | 1,719 | 11,740.77 | 0.0005 |
| Dimensional ETF Trust | 2025-10-31 | Dimensional US Sustainability Core 1 ETF | DFSU | 201 | 1,372.83 | 0.0001 |
| SCHWAB CAPITAL TRUST | 2025-10-31 | Schwab Total Stock Market Index Fund | SWTSX | 6,854 | 46,812.82 | 0.0001 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 2025-10-31 | U.S. MICRO CAP PORTFOLIO - INSTITUTIONAL CLASS | DFSCX | 1,381 | 9,432.23 | 0.0001 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 2025-10-31 | U.S. SMALL CAP PORTFOLIO - INSTITUTIONAL CLASS | DFSTX | 2,099 | 14,336.17 | 0.0001 |